Caris Life Sciences, Inc. filings document financial results, governance matters, financing arrangements and material company events for an AI TechBio precision medicine business. Form 8-K disclosures report quarterly and annual operating results, molecular profiling services revenue, clinical therapy selection activity, and Regulation FD updates tied to company presentations and diagnostic-development programs.
The company’s SEC record also includes a definitive proxy statement covering annual meeting proposals, director elections and auditor ratification. Other material-event filings describe senior secured credit facilities with subsidiary guarantees, amendments to bylaws affecting shareholder derivative proceedings, and capital-structure terms relevant to Caris’ public-company reporting obligations.
PHILLIPS T DANNY reported acquisition or exercise transactions in this Form 4 filing.
Caris Life Sciences, Inc. director Phillips T. Danny received an equity award reported as 13,192 shares of Common Stock, reflected as a grant or award of restricted stock units. The award was at a stated price of $0.00 per share and increased his direct holdings to 133,060 shares. The restricted stock units vest in accordance with the applicable grant agreement.
Minor Lloyd reported acquisition or exercise transactions in this Form 4 filing.
Caris Life Sciences, Inc. reported that director Lloyd Minor received a grant of 13,192 shares of Common Stock in the form of restricted stock units on 2026-08-14 at a stated price of $0.00 per share. These restricted stock units vest in accordance with the applicable grant agreement. Following this award, Minor directly holds 31,813 shares of the company’s Common Stock.
Caris Life Sciences, Inc. reported that director Joseph E. Gilliam received an equity award in the form of 13,192 shares of Common Stock on 2026-08-14, recorded as a grant or award acquisition at no cash price per share. Following this award, his directly held position increased to 29,321 shares. A footnote explains that the award consists of restricted stock units that vest in accordance with the applicable grant agreement.
Caris Life Sciences, Inc. reported that director David Paul Fredrickson received an equity compensation award. He acquired 13,192 shares of Common Stock on August 14, 2026, at a stated price of $0.00 per share, representing an award of restricted stock units that vest under the applicable grant agreement. Following this award, his directly held Common Stock position increased to 31,813 shares.
Vacirca Jeff L reported acquisition or exercise transactions in this Form 4 filing.
Caris Life Sciences director Jeff L. Vacirca received a grant of 13,192 shares of Common Stock on 2026-08-14, reported as an award of restricted stock units that vest under the applicable grant agreement. The award was recorded at $0.00 per share, and his direct holdings increased to 62,863 shares following the grant.
JOHANSEN LAURA I reported acquisition or exercise transactions in this Form 4 filing.
Caris Life Sciences, Inc. reported that director Laura I. Johansen received a grant of 13,192 shares of Common Stock in the form of restricted stock units on 2026-08-14. The award was recorded at $0.00 per share and increased her directly held position to 343,897 shares. According to the accompanying note, these restricted stock units vest in accordance with the applicable grant agreement.
HALBERT JON reported acquisition or exercise transactions in this Form 4 filing.
Caris Life Sciences, Inc. director Jon Halbert reported a grant of 13,192 restricted stock units of common stock on 2026-08-14 at $0.00 per share, vesting under an applicable grant agreement. Following this award, he holds 131,813 shares directly and indirect holdings of 652,062 shares through a family trust and 706,531 shares through LAH Investments, Ltd., where beneficial ownership is disclaimed except for his pecuniary interest.
Caris Life Sciences, Inc. received an updated passive ownership report from investment entities affiliated with J.H. Whitney. J.H. Whitney VI, L.P., together with J.H. Whitney Equity Partners VI, LLC, and managing members Paul R. Vigano and Robert M. Williams, Jr., report beneficial ownership of 11,256,615 shares of Caris common stock.
This position represents 4.0% of the outstanding common stock, with shared voting and dispositive power over all reported shares and no sole voting or dispositive power. The filing states that no other person has the right to receive, or direct the receipt of, dividends or sale proceeds from these securities. The amendment confirms that the reporting group now holds 5 percent or less of the class.
George H. Poste filed to sell common stock of CAI. A broker, Morgan Stanley Smith Barney LLC Executive Financial Services, is listed to handle the planned sale of 30,000 shares on 08/07/2026 on NASDAQ, with an aggregate value of $642,633.00.
The filing also notes a planned stock option exercise for 30,000 shares for cash on 08/07/2026, and discloses that 20,000 shares of common stock were sold on 08/03/2026 for $325,000.00 in the prior three months.
TSSP Sub-Fund HoldCo, LLC and Alan Waxman report updated ownership positions in Caris Life Sciences, Inc. common stock. As of June 30, 2026, they may be deemed to beneficially own 6,732,770 and 7,327,041 shares, respectively, reflecting 2.4% and 2.6% of the class based on 282,680,695 shares outstanding as of May 5, 2026. Both hold only shared voting and dispositive power over these shares through affiliated investment entities and disclaim beneficial ownership of securities held directly by those entities. They state that they no longer beneficially own more than five percent of the common stock, and this represents an exit reporting from five‑percent‑holder status.